OP 1

Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study
M. Santoro, Roma

OP 2

Durability and liver safety of InSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort
A. Lanari, Siena

OP 3

Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naive patients in a large clinical and resistance database
F. Lombardi, Roma

OP 4

Efficacy and tolerability of bictegravir/ tenofovir alafenamide/ emtricitabine as a switch strategy in a cohort of antiretroviral therapy treatment-experienced HIV-1-infected patients
F. Lagi, Firenze

OP 5

Viral rebound in pts with suppressed HIV-RNA on a 2 or 3-drug regimen: a comparison
A. Borghetti, Roma

OP 6

Optically traceable PLGA Nanoparticles improve the ability of darunavir to cross the blood brain barrier and inhibit MMP-9. Implications for the Treatment of HIV-Associated Neurological Disorders
S. Milella, Bari

OP 7

Effectiveness and long-term durability of rilpivirine-based single tablet regimens in a large cohort of HIV-infected patients. A preliminary analysis
R. Pincino, Genova

OP 8

Increase in body weight after a year of INI-exposure in a multicenter italian cohort
A. Ciccullo, Roma

OP 9

Treatment outcome among HIV-1 infected patients who started first-line ART pending GRT results from 2015 to 2018
D.F. Bavaro, Bari

OP 10

Retrospective analysis of reasons and characteristics of switches in a cohort of women affected by HIV infection referring to D. Cotugno Hospital, Naples, period 2017-2019
F.M. Fusco, Napoli

OP 11

Assessing the feasibility of 2-drug regimens as switch strategies in a multicenter cohort
A. Ciccullo, Roma

OP 12

Risk of failure in dual vs triple therapy in naïve HIV-patients: a meta-analysis
A. Russo, Caserta

OP 13

DAA treatment fails to restore the inflammatory profile both in HCV/HIV and in HCV infected patients
C. Agrati, Roma

OP 14

Sterol metabolism modulates susceptibility to HIV-1 Infection
I. Saulle, Milano

OP 15

Different amounts of activated or exhausted effector memory T cells among differentiated CD4+ or CD8+ T lymphocytes during primary, acute HIV infection
A. Cossarizza, Modena

OP 16

HIV+ patients: modulating effects of antiretroviral therapy on cytokines' profile and microbiota composition
G. Nannini, Firenze

OP 17

Association between subclinical atherosclerosis and IFN-I response in HIV-1 infected patients
G. De Girolamo, Roma

OP 18

p53/mir34a/SIRT1 loop and immune reconstitution relationship during chronic HIV infection
V. Bordoni, Roma

OP 19

Lower Immune Activation in Perinatally than in Horizontally HIV-Infected Adults
L. Taramasso, Milano

OP 20

Microbiota Composition in HIV-Positive and HIV-Exposed Uninfected Pediatric Subjects
S. Cannizzo, Milano

OP 21

Switching to integrase inhibitors is not linked to weight increase in young adults and adolescents perinatally infected with HIV, results from a 10-years observational study
L. Taramasso, Milano

OP 22

An atypical case of HIV-1 elite controller: 15 years of follow up
C. Fimiani, Roma

OP 23

Newly diagnosed HIV infected patients in Brescia, Northern Italy: epidemiological and clinical characteristics and possible targets of prevention and early diagnosis campaign
G. Zuglian, Brescia

OP 24

Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in HIV-infected patients with metabolic syndrome
L. Calza, Bologna

OP 25

Durability of InSTI-based regimen in geriatric people living with HIV. Data from the Italian Multicenter GEPPO Cohort
E. Focà, Brescia

OP 26

Weight gain and body composition changes in people living with HIV treated with Integrase Strand Transfer Inhibitors: a longitudinal assessment with Bioimpedance Vectorial Analysis
M. Poliseno, Bari

OP 27

Transmitted drug resistance in newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy
L. Calza, Bologna

OP 28

Same day treatment and rapid antiretroviral therapy introduction in a cohort of unselected newly-diagnosed HIV-positive individuals
G. Lapadula, Monza

OP 29

Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression
C. Muccini, Milano

OP 30

A descriptive analysis on dual regimens' discontinuations in a multicentre Italian cohort
D. Farinacci, Roma

OP 31

Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice
D. Armenia, Roma

OP 32

Does rapid initiation of ART at HIV diagnosis impact on virological response and retention in care? A single center experience (Brescia, Northern Italy)
N. Gregori, Brescia

OP 33

Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients
M. Masini, Siena

OP 34

Efficacy Safety and Tolerability of the switch from efavirenz/emtricitabine/tenofovir disoproxil on alternate days or continuous treatment to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV+ (EBONY Study)
M. Camici, Roma

OP 35

Allogenic hematopoietic stem cell transplantation in HIV-positive recipients: a case series
C. Oltolini, Milano

OP 36

Italian survey on clinicians' approach to Latent Tubercular Infection in people living with HIV
L. Caiazzo, Chieti

OP 37

A poor immunological recovery is associated with non-AIDS-defining cancers in the era of HAART: a case-control study
A. Emiliozzi, Siena

OP 38

HPV infection in HIV+, MSM patients followed at a large HIV Clinic in Northern Italy
E. Asperges, Pavia

OP 39

Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH)
V. Mazzotta, Roma

OP 40

Development and standardization of a real time PCR for the quantification of HTLV-1 proviral load
A. Primavera, Bologna

OP 41

Is pretreatment HIV-1 integrase resistance increasing? A large Italian centre experience
D. Canetti, Milano

OP 42

Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection
C. Muccini, Milano

OP 43

Evolving epidemiology of HIV/AIDS in Campania Region, 2008-19: is HIV/AIDS population in Campania different?
F.M. Fusco, Napoli

OP 44

Impact of boosted vs unboosted antiretroviral regimen on Dolutegravir plasma and intracellular pharmacokinetics
M. Ferrara, Torino

OP 45

Inflammatory and neurometabolite changes among patients switching away from efavirenz and their correlation with neurotoxicity: results from the sub-study of a randomized controlled trial
G. Lapadula, Monza

OP 46

Contribution of INSTI, BMI, physical activity or caloric intake to weight gain in PLWH
G. Dolci, Modena

OP 47

Cerebrospinal Fluid CXCL13 as a marker of Intrathecal Immunoglobulin Synthesis and Immune-activation in treatment-naïve People Living with HIV
M. Trunfio, Torino

OP 48

Evaluation of the association between cognitive performance and HAND diagnosis with the cognitive reserve in naïve HIV-infected patients
A.C. Brita, Roma

OP 49

Are Low vitamin D plasma levels associated with intrathecal immuneactivation in PLWH?
A. Vergori, Roma

OP 50

Gender differences in neurocognitive functions in PLWK
V. Delle Donne, Roma

OP 51

Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score
D. Morini, Modena

OP 52

NAFLD phenotype and prevalence across the menopause spectrum in women with HIV
J. Milic, Modena

OP 53

Incidence of diabetes in a cohort of PLWH people living with HIV in Perugia
E. Schiaroli, Perugia

OP 54

Standard vs higher dose of Rifampicin in patients with tuberculosis: a meta-analysis
V. Gentile, Caserta

OP 55

Rapid Detection of Mycobacterium tuberculosis DNA in pulmonary and extrapulmonary paraffinized samples by ddPCR
M. Antonello, Milano

OP 56

Pharyngeal contamination is a major driver for sexually transmitted infections epidemic in Men who have Sex with Men
R. Rossotti, Milano

OP 57

HCV infection in PWUD: a microelimination intervention in Rome
C. Taibi, Roma

OP 58

Direct-acting antiviral based treatment for HCV-infected persons who inject drugs: a multi-centre real-life study
L. Onorato, Napoli

OP 59

Are Non-Injecting Drug Users at risk of HCV-infection? Data from the San Patrignano cohort
A. Boschini, Coriano RN

OP 60

Real Life DAAs in a large cohort of people who use drugs with hepatitis C virus infection in Tor Vergata Hospital in Rome: adherence, efficacy and reinfections of a key population
T. Mulas, Roma

OP 61

Effects of HCV eradication on liver function in haemophilic HIV/HCV co-infected patients
V. Castelli, Milano

OP 62

Virological patterns of HCV-patients with failure to second generation direct-acting antivirals
M. Starace, Napoli

OP 63

Advanced liver disease outcomes after Hepatitis C viral eradication according to Human Immunodeficiency Virus coinfection in PITER cohort
M.G. Quaranta, Roma

OP 64

The combination of accurate serological and virological HBV markers can help to predict the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases
M. Alkhatib, Roma

OP 65

HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics
L. Onorato, Napoli

OP 66

HEV infection as an emergent public health issue: is it a concern for Italian blood donors?
L. Colagrossi, Milano

OP 67

HIV SelfTesting: a survey of self-tests availability in Italian Pharmacies
M. Maffeo, Milano

OP 68

Testing MSM in cruising venues
D. Zagato, Milano

OP 69

Behavioral aspects of MSM tested in community-based settings in 5 cities
M. Breveglieri, Bologna

OP 70

Pre-exposure prophylaxis in Modena: a wide spread of sexually transmitted infections among users attending the dedicated outpatient Clinic
C. Rogati, Modena

OP 71

Prevalence and risk factors for HPV anal infection in PrEP users: implications for vaccination policy
R. Rossotti, Milano

OP 72

NEETagers for the prevention of HIV and AIDS
V. Corallino, Perugia

OP 73

Clinical research integrated with narrative medicine to understand living and coping with HIV: TMC114FD1HTX4011 - DIAMANTE study
G.C. Orofino, Torino

OP 74

Women and HIV in prison setting: a data up date from the Italian ROSE network
E. Rastrelli, Viterbo

OP 75

First-year experience of an HIV clinic-based stop-smoking service
V. Spagnuolo, Milano

OP 76

Psychiatric disturbances are common in PrEP users: an analysis of comorbidities and comedications in real life
R. Rossotti, Milano

OP 77

The HIV-1 provirus excised by CRISPR/Cas9 may be integrated back into the cell genome in presence of the viral integrase
M. Lai, Pisa

OP 78

Analysis of HIV latency establishment and maintenance in CD4 T cells stimulated with IL-15
L. Manganaro, Milano

OP 79

Phylogenetic analyses applied to the study of transmission variants and their evolution in a HIV-1 positive couple
C. Fenizia, Milano

OP 80

Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays
I. Vicenti, Siena

OP 81

Initial characterization of elements detected and quantified exclusively on the basis of LTR region by Aptima HIV-1 Quant Dx dual-target assay in plasma of HIV-positive patients
A. Amendola, Roma

OP 82

Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data
C. Alteri, Milano

OP 83

HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR?
D. Armenia, Roma

OP 84

Viral tropism does not have any impact on CD4 recovery in acute HIV infection or AIDS
D. Vita, Milano

OP 85

Antiviral effect of HIV1 tat/rev siRNA carried by nanoparticles in human CD4+ T cell line
F. Falasca, Roma

OP 86

A real-life experience of vaccination strategies for HBV prevention in HIV patients
D. Tomasoni, Milano

OP 87

A successful experience of an immunization program in HIV-positive adults
G. Chieffo, Busto Arsizio VA

OP 88

Plasma exchange and dolutegravir exposure. A case report
M. Mussa, Alessandria

P 1

A descriptive analysis of bloodstream infections in patients living with HIV in a large Italian center

P 2

Amebic abscess of the spleen with severe sepsis and bronchial fistulisation in HIV+patient: case report

P 3

Pneumocystis jirovecii Pneumonia in HIV-negative Patients, a Frequently Overlooked Problem: Case Series from a Large Italian Center

P 4

Infection by Mycobacterium chimaera in two subjected undergoing cardiac surgery

P 5

A case of persistent relapsing abdominal mycobacterial infection requiring prolonged intravenous multi-drug treatment

P 6

Comparison of immunoassays for quantitative serum HBsAg

P 7

Cryptic HBV replication is frequently revealed in anti-HBc positive/HBsAg negative patients with HIV infection by applying a highly sensitive digital droplet PCR assay

P 8

The multidisciplinary group for HPV related disease and STD in Azienda Ospedaliera Universitaria Pisana (AOUP) Cisanello. An opportunity for HIV and HIV at risk people

P 9

Non-AIDS-defining cancers in a cohort of HIV positive patients

P 10

Case report on oncopathology in HIV-infected patients

P 11

Primitive NHL of bone in an HIV patient: case-report and review of literature

P 12

Alexithymia and cancer-related mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study

P 14

Oral Human Papillomavirus (HPV) detection in the context of the multidisciplinary HPV group in Azienda Ospedaliero-Universitaria Pisana (AOUP): a screening opportunity for HIV+ and other at risk-patients

P 15

HCC Recurrence 8 years post Liver-Transplant was linked to Hepatitis Delta Reactivation in a person living with HIV

P 16

Epidemiological analysis from a newly established anal HPV screening ambulatory

P 17

Behavioural and awareness changes in a HIV prevention program based on women empowerment in Uganda

P 18

Therapy burdens of Italian women living with HIV - Findings from the Positive Perspectives 2 Study

P 19

Transgender people and HIV

P 20

HIV-positive transgender people in follow-up at an Italian single tertiary care hospital in Florence: a cross-sectional study

P 21

HPV and bacterial vaginal infection impact on immune system in a cohort of HIV female population under suppressive ART

P 22

Qualitative analysis of significant clinical events in a cohort of patients after DAA treatment for chronic HCV infection after virological eradication

P 23

A fast track city micro-project to eradicate HCV infection in PLWHIV

P 24

A pilot intervention for HCV elimination among MSM in Rome: preliminary results

P 25

HCV eradication in people living with HIV in Sassari: the final countdown?

P 26

Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir failure in a young man with genotype 1a congenital HCV infection: a case presentation

P 27

Acute hepatitis C treatment with direct antiviral agents (DAAs) in patients with solid organ cancer

P 28

How to eliminate HCV in people who inject drugs? Preliminary results of a provincial multi-targeted approach involving three different settings: addictions services, prison, outreach mobile unit for active users

P 29

Innovative procedures for micro-elimination of HCV infection in persons who use drug (PWUD)

P 30

Short course therapy for chronic hepatitis C infection

P 31

DAA failure in HCV genotype 3: virological features and efficacy of re-treatment

P 32

Therapy of Hepatitis C in Prison: Experience of Systematic Treatment Program in Rome

P 33

Five years real-life experience with direct-acting antivirals for hepatitis C in a suburban setting in Rome: a retrospective analysis

P 34

Association Between Polymorphism in the Enhancer Gene and Hepatitis C Virus-induced Hepatocellular Cancer Risk

P 35

Genotyping and treatment issues with unusual 1e and 1g HCV subtypes from African subjects: report of two cases

P 36

Feasibility and impact of HCV treatment in a HRS in Milan

P 37

An effective strategy to achieve HCV micro-elimination: HCV test and treatment into two Harm Reduction Services in Milan

P 38

Long follow up of monocyte-macrophage immuneactivation markers in HCV mono-infected patients undergoing DAA treatment

P 39

EradichiamoCi: HCV micro-eradication project among 5 psychoactive substances user services using a DAA delivery strategy

P 40

Effect of direct antiviral therapy against HCV on CD4+ T cell count in patients with HIV-HCV coinfection

P 41

HCV treatment in PWID: a linkage to care model in Cagliari

P 42

Hepatitis A: has the outbreak ended?

P 43

Re-treatment of HCV infection following failure to DAAs: data from the SCOLTA cohort

P 44

HEV in Southern Italy. Still a chimera?

P 45

Evaluation of early HCC occurrence rate and its risk factors in HCV patients treated with direct-acting antivirals

P 46

Covid-19 in patients with HIV-1 infection: a single-centre experience in Northern Italy

P 47

A case of acute hepatitis C in a patient with HIV, occult HBV and SARS-CoV-2 co-infection

P 48

SARS-CoV-2 infection in a highly-experienced person living with HIV

P 49

SARS-CoV-2 infection in a HIV+ patient on darunavir-based ART monotherapy: a case report

P 50

COVID-19 in people living with HIV (PLWH): clinical picture, viral clearance, cellular and antibody response in a case series of a reference HIV/AIDS center in a COVID Hospital in Rome

P 51

Clinical course and viroimmunological impact of COVID-19 in HIV infected patients: a single-center report from Milan, Italy

P 52

Management of emergency COVID-19 in prison, Monza experience

P 53

Psychological impact and awareness of COVID-19 in young people with HIV

P 54

Review of lopinavir and darunavir use in SARS-CoV-2 and HIV co-infection: is it time to find another role and another actor?

P 55

Seroprevalence of SARS-CoV2 antibodies in paediatric HIV patients

P 56

Study of the types of the nervous system based on temperaments of HIV-infected patients

P 57

Persistent activation of CXCL13 axis in the Cerebrospinal fluid of People Living with HIV despite Central Nervous System Viral Suppression

P 58

Limited health literacy (HL) ability and low awareness of HL difficulties in people living with HIV

P 59

Evolution of cognitive performance at a 2 years follow-up in a group of HIV-infected patients

P 60

Cerebrospinal fluid viral replication and burden of resistance in HIV-1-infected people with multidrug resistance treated with Ibalizumab

P 61

In Vitro Effect of Efavirenz on Cultured Primary Astrocytes: Analysis of Neurotoxicity and Matrix Metalloproteinase Inhibition

P 62

Evaluation of Patient-Reported Outcomes (PROs) and cognitive performance in HIV naïve patients with advanced disease: results from the PRO-Advance study

P 63

Cerebrospinal Fluid anti-EBV Viral Capsid Antigen IgG Production associates with poorer Performance in Attention, Memory and Executive functions domains among People living with HIV

P 64

Cryptococcal meningitis in a young woman HIV late presenter: a case report

P 65

A multidisciplinary approach to imprint a successful long term adherence skill to Antiretroviral Therapy in naive patients: background and preliminary data of a pilot project of the GLAD group

P 66

Switching Dolutegravir/Abacavir/Lamivudine single tablet regimen (STR) to a less-costly multi-tablet regimen of Dolutegravir+Abacavir/Lamivudine (generic) in the setting of virologic suppression: data at 48 weeks

P 67

Complementary-alternative medicines and self prescribed drugs use in women living with HIV

P 68

Availability of rapid HIV self-test in Italian pharmacies: a survey

P 69

REducing LAte Presenters Patients rate in Milan area (RELAPP Study): preliminary results

P 70

May administering routine HIV test be useful to uncover the iceberg in a University Hospital setting? Our experience

P 71

High rates of lost-to-follow-up among naive HIV+ female population: real-life data from UOC "Immunodeficienze e Malattie Infettive di Genere", D. Cotugno Hospital, Naples, 2017-19

P 72

Risk Factors for Late HIV Presentation in a Tertiary Care University Hospital

P 73

Epidemiology and clinical characteristics of HIV/AIDS among foreign in Campania Region, 2008-19: which differences with Italian population?

P 74

The efficacy of cART regimens and retention in care in an HIV-infected cohort of naïve patients

P 75

Characterization of HIV-1 transmission dynamics in North and Central Italy over the years 2012-2019

P 76

"EXTERNA": QoL Perception in PLWHIV during ID checkup

P 77

HIV screening in migrant population living in "ghetti" in Apulia

P 78

Geographic distribution of delayed presentation of HIV infection in HIV Emilia Romagna Surveillance System

P 79

Immunological evolution of a cohort of HIV-2 infected patients: peculiarities of an underestimated infection

P 80

HIV testing offer and services to improve linkage to Care in public services for HIV test: a survey

P 81

Gap in care and loss to follow up due to administrative barriers among migrants living with HIV in the city of Padova

P 82

Long-term survivors in a cohort of HIV+ patients diagnosed between 1985 and 1994: predictive factors associated with more than 25 years of survival

P 83

New diagnoses of HIV infection: what has changed in 10 years

P 84

Acne vulgaris as possible Immune Recovery Folliculitis driven by the lymphocyte T CD8+ immunological recovery in naïve and experienced patients

P 85

Influence of HLA haplotype on immunological recovery in HIV-infected patients

P 86

Oxidative Stress and gut microbiota composition in primary HIV infection

P 87

PrEP awareness and attitudes in a survey among Italianclinicians

P 88

PrEP: the stories about who used the therapy

P 89

Young People Inform Young People - Speak to the students with the Peer Section of the School Project

P 90

Problems and difficulties in the management of a PrEP clinic

P 91

Post-exposure prophylaxis in real life

P 92

Determinants of drug start, schedule change and discontinuation in PrEP users

P 93

No increased risk of adverse events and sexually transmitted infections in PrEP users despite the rise in condomless sex

P 94

PreP: psychological and emotional aspects

P 95

PrEP use amongst MSM in Italy: data from the EMIS 2017 survey

P 96

Pre-Exposure Prophylaxis (PrEP): the one-year experience of the first dedicated service of Tuscany Region in S.M.Annunziata Hospital, Florence

P 97

In vitro effect of Castanea Sativa Mill. bark extract (ENC®) on HIV-1 infection: a potential microbicide

P 98

Undetectable versus low level HIV viremia on patients taking antiretroviral therapy

P 99

Quantification of total HIV-1 DNA in the peripheral blood of naïve and treated patients

P 100

HIV2-Vpx modulation of MDDCs-CD4+ T cells HIV-1 Trans Infection

P 101

New potential anti-HIV agents: the antimicrobial peptide Temporin L

P 102

Fast and sensitive qPCR assay for the concomitant quantification of bacterial 16S rDNA and HIV-1 DNA: preliminary data from blood samples of HIV-1 infected patients

P 103

HIV-DNA quantification in PBMC: evaluation of two new real-time PCR commercial test

P 104

Influence of HIV-1 V2 domain characteristics on immunological recovery under ART

P 105

Susceptibility to HIV-1 integrase inhibitors in HIV-1 sub-subtype A6 isolates

P 106

Residual phenotypic susceptibility to second generation NNRTI in multidrug resistant HIV-1 from the PRESTIGIO Registry

P 107

In vitro activity of Islatravir against HIV-1 mutants harboring multiple NRTI resistance mutations

P 108

Does HLA-C binding stability affect HIV-1 infection?

P 109

Genotipic Resistance test in rapid ART era

P 110

Tuberculous and non tuberculous mycobacterial extra-pulmonary infections in HIV

P 111

Short-Cycle Therapy comprising a lamivudine and dolutegravir regimen of 5 days on and 2 off in a small cohort of suppressed HIV-infected patients

P 112

Are 2-drug regimens with lamivudine plus boosted-PI still a feasible option in the era of integrase inhibitors? A multicenter analysis

P 113

HIV-DNA decay in ART-naïve patients starting a DTG-based dual vs triple therapy

P 114

Side effects detected in HIV-positive patients depending on the ART regimen

P 115

Safety and tolerability of tenofovir alafenamide (TAF) on bone mineralization and renal function in a cohort of young adults with HIV infection

P 116

A rare case of acute tubular necrosis tenofovir alafenamide-related

P 117

New cases of diabetes dolutegravir-associated in HIV patients: a case series

P 118

Reduced Bone catabolism and inflammation in patients switching to TAF-containing cART

P 119

Viral outcome on tailored treatment strategyusing cost saving antiretroviral (ARV)

P 120

The need for reducing both ARV and medicine-taking burdens among Italian PLHIV - Findings from the Positive Perspectives 2 Study

P 121

Switch to darunavir/cobicistat/emtricitabine/tenofovir alafenamide in HIV-infected patients not receiving protease inhibitors-based regimens

P 122

Nevirapine-based therapy in the twenty-first century: still an effective and safe long-term choice

P 123

Switch to dual therapy (3tc+dtg or rpv+dtg) in a cohort of people living with HIV: experience from real life

P 124

Changes in lipid profile and subclinical atherosclerosis after switching to tenofovir alafenamide (TAF) containing antiretroviral regimens in people living with HIV

P 125

An early proactive switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/T/TAF) is effective in maintaining virologic control, reducing low level viral replication and continuing immunological recovery in patients with a primary HIV-1 infection (PHI). An interim analysis of a phase IV clinical trial (ESTER study)

P 126

Efficacy of dolutegravir versus darunavir in first-line regimens according to resistance mutations and viral subtype

P 127

Switch to dolutegravir-based dual therapy: outcomes in ART-experienced patients

P 128

Evaluation of efficacy and durability of raltegravir once-daily: real-life data from an Italian Center

P 129

Impact on CD4 count and CD4/CD8 ratio of 3 different integrase inhibitor-based regimens in naïve and experienced patients

P 130

Alteration of serum lipid profiles in HIV/HCV co-infected patients under treatment with HAART/DAAs combined therapy

P 131

Plasma viral load decay in first-time INSTI-users. A comparison between raltegravir, elvitegravir/cobicistat and dolutegravir

P 132

Metabolic profile changes after switching from a PI- to an INI-based regimen in the maintenance treatment of HIV infection

P 133

Evaluation of lipid profile in HIV naive patients, treated by TAF-based regimens

P 134

Younger Age, Male Gender and HCC presence are Associated to anti HCV-DAA failure

P 135

Reactivation of occult HBV infection in HIV patients treated with direct-acting antivirals for chronic hepatitis C: a retrospective study

P 136

DAA failure in HCV genotype not 1: virological features and efficacy of re-treatment

P 137

Virological features and efficacy of re-treatment in HCV patients: a real experience in Southern Italy

P 138

Overall survival at 3, 5 and 10 years of HIV-positive patients who underwent liver transplantation at the University Hospital of Ancona

P 139

Viro-immunological and histological characterization of a case of HBV-related hepatitis with immune reconstitution inflammatory syndrome after treatment initiation for HBV/HIV-1 co-infection with bictegravir/emtricitabine/tenofovir alafenamide

P 140

Indirect hyperbilirubinemia and jaundice during chronic hepatitis C in an HIV-infected patient treated with glecaprevir/pibrentasvir (GLE/PIB) and antiretroviral therapy (ART). The first reported case in Italy

P 141

Current management of hepatitis B in sclerosis patients treated with disease-modify therapies

P 142

Effect of 12-week physical activity program on sarcopenia measures in people living with HIV

P 143

Reasons for starting D/C/F/TAF and characteristics of patients enrolled in an Italian non-interventional study: the DIAMANTE (TMC114FD1HTX4011) study

P 144

HIV-1 DNA quantification: Comparative analysis and validation of two commercial qPCR assays

P 145

Intestinal Alkaline Phosphatase levels in HIV infected patients

P 146

Diagnostic performance of different screening strategies for the prevention of HPV-related anal cancer

P 147

Syphilis in newly HIV-1 diagnosed from 2010 to 2019: a single center report

P 148

3TC+DTG versus FTC/TAF plus an integrase inhibitor: comparing changes in bone mineral density

P 149

HTA analysis of glatiramer and neuroprotection in HIV-related comorbidities

P 150

Low Vitamin D concentration is associated with NAFLD and metabolic syndrome in HIV-1-infected patients on combination antiretroviral therapy

P 151

Cardiovascular disease risk markers in a small cohort of HIV-infetcted patietns switched from abacavir/lamivudine/dolutegravir to lamivudine plus dolutegravir

P 152

Prevalence and incidence of Hepatic Steatosis in SCOLTA cohort

P 153

Factors associated with immunosenescence during early adulthood in HIV-infected patients after durable efficient cART

P 154

Metabolic changes in HIV-infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a randomized study (Be-OnE Study)

P 155

A structured smoking cessation intervention in a single centre in patients living with HIV

P 156

Physical activity levels in HIV+ cohort of Pavia

P 157

Machine learning vs Knowledge based approach in health outcomes' prediction in HIV

P 158

Use of two drugs regimens (2DR) in a cohort of HIV-infected geriatric patients (GEPPO cohort)

P 159

Poor concordance between liver stiffness and non-invasive fibrosis scores in HIV-1 monoinfected virologically suppressed patients

P 160

Obesity and overweight among people living with HIV in the province of Pavia: a cross-sectional study

P 161

Evaluation of resting energy expenditure and body mass composition in a cohort of HIV infected patients on antiretroviral treatment

P 162

Archi-Prevaleat project. A National Register of color-Doppler ultrasonography of the epi-aortic vessels in Patients Living with HIV

P 163

Rethinking the necessity of intrapartum zidovudine administration. A small case series from a single centre in the north of Italy

P 164

Antiviral activity of 1-(41-chlorophenyl)-4-(42-methylphenyl)-5,6,7,8-tetrahydro-2a,4a-diazacyclopenta[cd]azulene-2-carboxylic acid derivatives

P 165

Antiviral activity of of 6-(4-methylbenzyl)-3-arylamino-4н-[1,2,4]triazin-5-оne derivatives against yellow fever

P 166

Dolutegravir, emtricitabine/tenofovir alafenamide fumarate absorption in a gastrectomized HIV-positive patient

P 167

A survey as a chance of education on U=U in Italian general population

P 168

Development and management of a web-based system able to collect and analyse data about self-diagnostics HIV test - ULISSE

P 169

HIV prescriptivetrend 2018 vs 2019 in a teaching hospital in Rome

P 170

HAARTisticamente An unusual fashion show

P 171

"La prevenzione va in tournèe" a social experiment and on the field experience on HIV/STIs and social integration

P 172

Mono-symptomatic therapeutical group for Chemsex users - an ongoing experience

P 173

HIV rapid testing outside healthcare facilities: diagnostic and educational tool

P 174

Changes in causes of death of people living with HIV in a large teaching hospital in Rome

P 175

The PLWH perception of long acting injectable therapy

P 176

Cohort observational study and HIV brochure in a teaching hospital in Rome

P 177

HIV Self-Testing in Italy: a usability survey of clients using self-tests at two community organisations

P 178

Counselling and HIV rapid test for marginalized groups: data from an Emilia-Romagna Region project*

P 179

School and HIV. Cognitive and Emotional aspects for effective communication

P 180

Sardinia, first ever institutional Hiv testing and TasP promotion campaign: the communication strategy of Lila Cagliari team

P 181

"TEST WITH THE STAR": a pre-counselling "dog assistance" pilot project during HIV-HCV screening campaign "1st December World AIDS Day. Communities make the difference. Union makes the difference! HIV LATINA CHALLENGE 2019. U = U"

P 182

Test, condom and chems: how the habits of people in Milan change. A test experience in a premise

P 183

Coming out surrealista

P 184

App as tool for Prevention among students: the launch of a new counselling service about HIV/STIs promoted by Anlaids Onlus

P 185

PrEP between desire and needing: 2020 update

P 186

Free anonymous HIV Testing and linkage to care activities: data from the Milano Check Point

P 187

Pleasure and sociality as drivers of chemsex among Italian gay men living with HIV

P 188

The multidisciplinary (MD) HPV group in Azienda Ospedaliera Universitaria Pisana (AOUP). Impact of HIV-HPV sinergy. Preliminary data analysis

P 189

HIV and STIs amongst MSM in Italy: data from the EMIS 2017 survey

P 190

Never Infected. Perception of the Risk of HIV Infection in Case of Undetectable Virus

P 191

Linkage to care in HIV: the point of view of people with recent diagnosis

P 192

AIDS and other sexually transmitted diseases: what do young people know? - a Cross Sectional Study

P 193

Prevalence and risk factors associated with new diagnosis of STI in individuals attending an in-hospital STI clinic

P 194

SRHR Sensitization and Education activities from Medical Students

P 195

"Senza la C" - HCV diagnosis and treatment for people who inject drugs in a community-based setting: results from an experience in Bologna

P 196

WE TEST - National community-based HIV prevention program

P 197

Anti-body response to pneumococcical vaccination in HIV patient after supplementation with probiotic

P 198

Adherence to the influenza vaccination campaign: experience of a large clinical center

P 199

HPV oral infection and clearance in Men who have Sex with Men and Transgender Women undergoing nonavalent vaccination: preliminary results from an interventional study

P 200

Immunization status in a pediatric transplanted cohort: the Federico II teaching hospital experience

P 201

Vaccination knowledge, attitudes and practices in patients with HIV: a cross-sectional survey

P 202

Success rate and evolution of immunological parameter over first vaccination against HBV with Fendrix© in People Living with HIV

P 203

Organization of a dedicated vaccination service for HIV-positive patients, Pre-Exposure Prophylaxis (PrEP) users, and patients in care for sexually transmitted infections (STIs): the experience of S.M.Annunziata Hospital, Florence

P 13

Kaposi Sarcoma among AIDS-presenters in Modena: could it be a cluster?